Toddlers Age 1-2 With CF Can Now Be Treated With Kalydeco in Canada
Jan 29, 2019 07:00 am | Alice Melão
Health Canada has approved the use of Kalydeco (ivacaftor) in toddlers age 1-2 years with certain genetic mutations that prevent the correct functioning of the CFTR protein, the therapy’s developer announced. With a pill taken twice a day, Kalydeco, by Vertex Pharmaceuticals, makes it possible to resolve the underlying cause of cystic fibrosis (CF) in people with […]
The post Toddlers Age 1-2 With CF Can Now Be Treated With Kalydeco in Canada appeared first on Cystic Fibrosis News Today.